Aardvark Therapeutics, Inc.
AARD
$5.39
$0.020.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.07% | 46.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.65% | 11.70% | |||
| Operating Income | -5.65% | -11.70% | |||
| Income Before Tax | -7.86% | -13.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.86% | -13.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.86% | -13.57% | |||
| EBIT | -5.65% | -11.70% | |||
| EBITDA | -5.66% | -11.72% | |||
| EPS Basic | -7.52% | -13.44% | |||
| Normalized Basic EPS | -7.16% | -13.75% | |||
| EPS Diluted | -7.52% | -13.44% | |||
| Normalized Diluted EPS | -7.16% | -13.75% | |||
| Average Basic Shares Outstanding | 0.32% | 0.11% | |||
| Average Diluted Shares Outstanding | 0.32% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||